Bactolife raised $35 million in Series B funding to commercialize its binding protein gut health ingredients.
- Amount
- $35M
- Stage
- Series B
- Announced
- 6 January 2026
- Leads
- Cross Border Impact Ventures, EIFO (Danish Export and Investment Fund)
- Other investors
- Novo Holdings, Athos, Gates Foundation
- Use of funds
- Execute human study program, scale manufacturing and supply, commercialize human and animal health ingredients.
- Checked
- Amount and date checked against the press source